Cansino has made positive progress in commercialization and R&D recently. We look forward to the performance of MCV4 in H2. Its valuation in HKEX is “ridiculously low”,but A-share can be better option
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.